Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.

What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

The 76-year-old Oscar winner got serious about her health following her diagnosis for type 2 diabetes in 2017, but there was ...

Not long ago, the FDA announced there's no longer a shortage of Ozempic, Wegovy, Zepbound or similar drugs used for weight ...

Type 3c diabetes, also known as pancreatogenic diabetes, is a form of diabetes that develops as a direct result of disease or damage to the pancreas. It is different from type 1 and type 2 diabetes ...

Researchers have launched a phase 1/2 clinical trial to see if osteoporosis medication can enhance beta cell health among people living with early type 1 diabetes. During the trial, scientists from ...

A direct connection exists between the pancreas and diabetes. The pancreas is an organ deep in your abdomen behind your stomach. It’s an important part of your digestive system. The pancreas ...

A new study sheds light on changes to the fetus's bile acid, which affects ... New Tech for Managing Type 1 Diabetes Is Effective for Older Adults Mar. 11, 2025 — New research suggests that ...

Type 1 diabetes is an autoimmune condition associated with genetics and may develop suddenly. Type 2 diabetes often develops over time, with obesity and a lack of exercise as the main risk factors.